News and Press


Ventria Bioscience Appoints Seymour Fein, M.D. as Chief Medical Officer

FORT COLLINS, Colo. – February 13, 2014 – Ventria Bioscience announced today that Seymour Fein, M.D., has been appointed as the company’s new Chief Medical Officer. Dr. Fein will be responsible for the company’s clinical development and medical affairs functions.

“The expansion of our clinical development capabilities was a necessary and significant step for Ventria Bioscience as our therapeutic product-development pipeline advances,” said Scott Deeter, president and chief executive officer of Ventria Bioscience. “Dr. Fein will oversee our current clinical pipeline and drive future product development, clinical study design, and budgets so that Ventria Bioscience’s products meet the medical needs of patients and lead to commercial success.”